Nov 26 (Reuters) - Mayne Pharma Group Ltd MYX.AX :
* Says "expect to expand our portfolio in dermatology and other attractive specialist-driven therapeutic areas"
* Continue to forecast that doryxtm will deliver earnings guidance of US$2.7M of EBITDA on average per month during FY 2016
* Says expect to spend more than $25M in research and development in this financial year
* Source text for Eikon ID:nASX7JyRZ9